ווטריינט 200 מ"ג
국가: 이스라엘
언어: 히브리어
출처: Ministry of Health
이 제품에 대한 일부 문서는 현재 사용할 수 없습니다. 고객 서비스에 요청을 보내면 가능한 빨리 알려 드리겠습니다.
요청을 보내십시오.
요청을 보내십시오.
유효 성분:
PAZOPANIB AS HYDROCHLORIDE 200 MG
제공처:
GLAXO SMITH KLINE (ISRAEL) LTD
ATC 코드:
L01XE11
약제 형태:
FILM COATED TABLETS
관리 경로:
PER OS
Manufactured by:
GLAXO OPERATIONS UK LIMITED
치료 그룹:
PAZOPANIB
치료 징후:
Renal cell carcinoma (RCC)Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
승인 날짜:
2011-01-01
